All evidence | Drugs and Technologies | Cochrane Database of Systematic Reviews, Scottish Medicines Consortium - SMC, British National Formulary for Children - BNFc, Royal College of Psychiatrists - RCPsych, Brain Tumour Charity, Arthritis Research UK, Canadian Paediatric Society, British HIV Association - BHIVA, European Society of Gastrointestinal Endoscopy | Medicines Current Awareness | Search results page 1 | Evidence search

Add this result to my export selection

Secukinumab (Cosentyx®) accepted for use within NHS Scotland for treatment of active non-radiographic axial spondyloarthritis

Source:

Scottish Medicines Consortium - SMC (Remove filter)

Published by Scottish Medicines Consortium, 18 January 2021

Approval is based on a randomised phase III study, in which secukinumab, compared with placebo, significantly improved symptoms in adults with active non-radiographic axial spondyloarthritis.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Daratumumab subcutaneous injection (Darzalex®) accepted for use within NHS Scotland

Source:

Scottish Medicines Consortium - SMC (Remove filter)

Published by Scottish Medicines Consortium, 18 January 2021

Following submission under the orphan medicine process, SMC has approved daratumumab in combination with bortezomib, thalidomide and dexamethasone for treatment of adult patients with newly diagnosed...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Melatonin prolonged-release (Slenyto®) not recommended for use within NHS Scotland for treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome

Source:

Scottish Medicines Consortium - SMC (Remove filter)

Published by Scottish Medicines Consortium, 18 January 2021

Slenyto® compared with placebo, increased total sleep time and sleep onset latency in children who had an insufficient response to sleep hygiene measures. However, the company did not present a...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Brentuximab vedotin (Adcetris®) accepted for use within NHS Scotland for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL)

Source:

Scottish Medicines Consortium - SMC (Remove filter)

Published by Scottish Medicines Consortium, 18 January 2021

Approval based on phase III study, in which brentuximab in combination with cyclophosphamide, doxorubicin and prednisone was associated with a significant improvement in progression-free survival vs.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Brigatinib (Alunbrig®) accepted for use within NHS Scotland for treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer

Source:

Scottish Medicines Consortium - SMC (Remove filter)

Published by Scottish Medicines Consortium, 18 January 2021

Approved for patients previously not treated with an ALK inhibitor; offering an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors for this indication.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Entrectinib (Rozlytrek®) accepted for use within NHS Scotland for treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)

Source:

Scottish Medicines Consortium - SMC (Remove filter)

Published by Scottish Medicines Consortium, 18 January 2021

Approved for patients not previously treated with ROS1 inhibitors; based on a phase II study in patients with ROS1-positive advanced NSCLC, in which the objective response rate was 72%.

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Fostamatinib (Tavlesse®) accepted for restricted use within NHS Scotland for treatment of chronic immune thrombocytopenia (ITP) in adults

Source:

Scottish Medicines Consortium - SMC (Remove filter)

Published by Scottish Medicines Consortium, 18 January 2021

Restricted to treatment of patients with severe symptomatic ITP or with a high risk of bleeding who have not had a suitable response to other therapies, including a thrombopoietin receptor-agonist...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour

Source:

Cochrane Database of Systematic Reviews (Remove filter)

Published by Cochrane Database of Systematic Reviews, 10 December 2020

This review (7 trials; n=7,817) found IV administration of oxytocin is more effective than intramuscular administration in preventing postpartum haemorrhage during vaginal birth, with a comparable...

Read Summary

Type:

Systematic Reviews (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Avatrombopag (Doptelet®) accepted for use within NHS Scotland for treatment of severe thrombocytopenia in adult patients with chronic liver disease scheduled to undergo an invasive procedure

Source:

Scottish Medicines Consortium - SMC (Remove filter)

Published by Scottish Medicines Consortium, 07 December 2020

Approval is based on two phase III studies which showed avatrombopag was superior to placebo for proportion of patients who did not require a platelet transfusion or any rescue procedure for bleeding...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Mexiletine (Namuscla®) accepted for use within NHS Scotland for symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders

Source:

Scottish Medicines Consortium - SMC (Remove filter)

Published by Scottish Medicines Consortium, 07 December 2020

Approval of this resubmitted application is based on a short-term, phase III, crossover study; results of which showed that mexiletine significantly improved muscle stiffness compared with placebo...

Read Summary

Type:

Prescribing and Technical Information (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Search results

Filter

Evidence type

Area of interest

Source

Filter by Date

50 results for All evidence

Secukinumab (Cosentyx®) accepted for use within NHS Scotland for treatment of active non-radiographic axial spondyloarthritis

Daratumumab subcutaneous injection (Darzalex®) accepted for use within NHS Scotland

Melatonin prolonged-release (Slenyto®) not recommended for use within NHS Scotland for treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome

Brentuximab vedotin (Adcetris®) accepted for use within NHS Scotland for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL)

Brigatinib (Alunbrig®) accepted for use within NHS Scotland for treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer

Entrectinib (Rozlytrek®) accepted for use within NHS Scotland for treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)

Fostamatinib (Tavlesse®) accepted for restricted use within NHS Scotland for treatment of chronic immune thrombocytopenia (ITP) in adults

Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour

Avatrombopag (Doptelet®) accepted for use within NHS Scotland for treatment of severe thrombocytopenia in adult patients with chronic liver disease scheduled to undergo an invasive procedure

Mexiletine (Namuscla®) accepted for use within NHS Scotland for symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders